Valneva plunges then recovers: what’s really happening with the stock and the VLA2001 vaccine?
If you've followed this French biotech for the past decade, you know that rollercoaster rides are part and parcel of daily life. But what happened to Valneva this week would make even the most seasoned pros wince. The stock suddenly broke below €4.35, flirting with €3.89 before showing some signs of a rebound. This kind of jolt always sends retail investors into a tailspin. So, what's behind this latest about-face?
Solid financial results, but a fickle market mood
We need to put things in context. Based on the financial results released a few days ago, the balance sheet is solid. Revenue is there, cash flow is steady, and the development of vaccine candidates is progressing. So why the drop? Because in the stock market, especially for a company of this size, the devil is in the expectations. The market was probably expecting more aggressive guidance, or more earth-shattering announcements regarding the progress of the famed Lyme disease vaccine.
But we're talking about science here, not magic. Thomas Lingelbach, the CEO, reiterates this every time he speaks: developing preventative vaccines for infectious diseases isn't something you can do at the snap of your fingers. VLA15 (the name of their Lyme disease candidate) is arguably the most closely watched project in the industry because if it succeeds, it will be the first modern-day "golden goose" for this disease. But as long as the final go-ahead isn't secured, the share price will remain under pressure.
VLA2001, the COVID vaccine that changed the game... and expectations
We shouldn't forget where we've come from. With VLA2001, Valneva proved it could hold its own with the big players. This inactivated virus vaccine, used particularly within strict protocols, was a much-needed boost. For those following the regulatory side, the Generic Protocol for ECDC Studies of COVID-19 Vaccine Effectiveness Against Confirmed SARS-CoV-2 Using Healthcare Worker Cohorts: Version 3.0 remains a key reference for assessing real-world effectiveness.
But today, the market has a short memory. The COVID era is behind us, and investors don't want to hear about legacy vaccines anymore. They want something new, something disruptive. And right now, Valneva finds itself in a bit of a lull, caught between the end of the COVID euphoria and the still-ongoing maturation of its Lyme pipeline. This is often the phase where stock prices suffer the most because traders don't like a vacuum. They prefer blockbuster quarterly announcements to quiet waiting periods.
Reasons to be optimistic (or not) going forward
So, what should you do if you have Valneva in your portfolio or are eyeing the stock? Here are a few points worth considering:
- Cash and visibility: The company has secured funding and partnerships. It's not going to disappear overnight. The financial results confirm this: there's enough substance to keep things on track until the next major milestones.
- The Lyme timeline: VLA15 is the primary catalyst. The next data readouts, if positive, could literally send the stock soaring. It's a binary situation, but with enormous potential.
- Thomas Lingelbach's experience: He's no novice. He's weathered far fiercer storms than this minor stock market chill. His strategy, focused on developing preventative vaccines, remains consistent.
In the stock market, emotions are often amplified with this kind of stock. The drop below €4.35 triggered stops and automatic selling, which mechanically amplified the movement. That's classic. What's more interesting is to see if the stock manages to stabilise above this psychological threshold in the coming sessions. If it does, the technical rebound could be just as brutal as the fall.
Let's not kid ourselves, betting on Valneva today is betting on the biotech of tomorrow, with all the risks and rewards that entails. But those who held on during the uncertain phases for VLA2001 will remember this: when the science delivers, the market always eventually follows.